Discussing Post Hoc Analyses from the REACH2 Trial

home / between-the-lines / discussing-post-hoc-analyses-from-the-reach2-trial

Nelson J. Chao, MD, MBA, and Michael Grunwald, MD review Acute Graft-Versus-Host Disease diagnosis and treatment before engaging with two REACH2 trial post hoc analyses, sharing clinical implications and key takeaways.

Understanding Acute Graft-Versus-Host Disease

EP. 1: Understanding Acute Graft-Versus-Host Disease

Nelson J. Chao, MD, MBA;Michael Grunwald, MD
March 31st 2023

Nelson J. Chao, MD, MBA, and Michael Grunwald, MD introduce acute Graft-Versus-Host Disease (GvHD), sharing how it is diagnosed, how it differs from chronic GvHD, and common signs and symptoms.

Standard Treatments for Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

EP. 2: Standard Treatments for Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

Nelson J. Chao, MD, MBA;Michael Grunwald, MD
March 31st 2023

Drs Chao and Grunwald review available treatment options as informed by NCCN guidelines for patients with steroid-refractory acute Graft-Versus-Host Disease.

REACH 2 Post Hoc Analysis Review: and The Impact of Cytopenias on Patient Outcomes

EP. 3: REACH 2 Post Hoc Analysis Review: and The Impact of Cytopenias on Patient Outcomes

Nelson J. Chao, MD, MBA;Michael Grunwald, MD
April 7th 2023

Two subject matter experts discuss a post hoc analysis of the REACH2 trial, focusing on the impact of cytopenias on treatment outcomes in patients with steroid-refractory acute Graft-Versus-Host Disease.

Post Hoc Analysis Review: REACH2 and Early vs. Late Treatment with Ruxolitinib

EP. 4: Post Hoc Analysis Review: REACH2 and Early vs. Late Treatment with Ruxolitinib

Nelson J. Chao, MD, MBA;Michael Grunwald, MD
April 7th 2023

Panelists engage with a post hoc analysis of the REACH2 trial comparing early versus late treatment with ruxolitinib in patients with steroid-refractory acute Graft-Versus-Host Disease.

Key Takeaways from Two Post Hoc Analyses of the REACH2 Trial

EP. 5: Key Takeaways from Two Post Hoc Analyses of the REACH2 Trial

Nelson J. Chao, MD, MBA;Michael Grunwald, MD
April 14th 2023

Nelson J. Chao, MD, MBA, and Michael Grunwald, MD draw conclusions from two post hoc analyses of the REACH2 trial and share clinical pearls for community clinicians treating patients with acute Graft-Versus-Host Disease.

Recap: Post Hoc Analysis Highlights Impact of Cytopenias on Response Rates in Acute GVHD

EP. 6: Recap: Post Hoc Analysis Highlights Impact of Cytopenias on Response Rates in Acute GVHD

ONCOLOGY Staff
July 23rd 2023

Experts review treatment options for acute graft-versus-host disease and discuss data from post hoc analyses of the REACH2 trial.